Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena Sophia Gleerup

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Alzheimer'S Disease Reports|May 9, 2022
The Added Value of Cerebrospinal Fluid Neurofilament Light Chain to Existing Diagnostic Methods and Biomarkers in a Mixed Memory Clinic Cohort of Consecutive PatientsHelena Sophia Gleerup, Anja Hviid Simonsen, Peter Høgh
Disease Markers|June 14, 2019
Biomarkers for Alzheimer's Disease in Saliva: A Systematic ReviewHelena Sophia Gleerup, Steen Gregers Hasselbalch, Anja Hviid Simonsen
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersMathias Holsey Gramkow, Helena Sophia Gleerup, Anja Hviid Simonsen, et al.
Ebiomedicine|May 11, 2021
Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic populationHelena Sophia Gleerup, Camilla Steen Jensen, Peter Høgh, et al.
Journal of Alzheimer'S Disease Reports|June 14, 2023
Progression of Blood-Brain Barrier Leakage in Patients with Alzheimer's Disease as Measured with the Cerebrospinal Fluid/Plasma Albumin Ratio Over TimeChristian Sandøe Musaeus, Helena Sophia Gleerup, Steen Gregers Hasselbalch, et al.
Journal of Alzheimer'S Disease : JAD|April 14, 2020
Cerebrospinal Fluid/Plasma Albumin Ratio as a Biomarker for Blood-Brain Barrier Impairment Across Neurodegenerative DementiasChristian Sandøe Musaeus, Helena Sophia Gleerup, Peter Høgh, et al.
Clinical Biochemistry|December 12, 2022
Cerebrospinal fluid glucose is not altered in patients with dementiaCamilla Steen Jensen, Helena Sophia Gleerup, Christian Sandøe Musaeus, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 14, 2023
Neurofilament light chain levels in serum among a large mixed memory clinic cohort: Confounders and diagnostic usefulnessAnja Hviid Simonsen, Helena Sophia Gleerup, Christian Sandøe Musaeus, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 17, 2025
Plasma biomarkers of amyloid, tau, astrogliosis, and axonal injury in a mixed memory clinic cohortHelena Sophia Gleerup, Anja Hviid Simonsen, Lana Grötschel, et al.
Frontiers in Aging Neuroscience|May 27, 2021
Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic PopulationHelena Sophia Gleerup, Federica Sanna, Peter Høgh, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Alzheimer'S Disease Reports|May 9, 2022
The Added Value of Cerebrospinal Fluid Neurofilament Light Chain to Existing Diagnostic Methods and Biomarkers in a Mixed Memory Clinic Cohort of Consecutive PatientsHelena Sophia Gleerup, Anja Hviid Simonsen, Peter Høgh
Disease Markers|June 14, 2019
Biomarkers for Alzheimer's Disease in Saliva: A Systematic ReviewHelena Sophia Gleerup, Steen Gregers Hasselbalch, Anja Hviid Simonsen
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersMathias Holsey Gramkow, Helena Sophia Gleerup, Anja Hviid Simonsen, et al.
Ebiomedicine|May 11, 2021
Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic populationHelena Sophia Gleerup, Camilla Steen Jensen, Peter Høgh, et al.
Journal of Alzheimer'S Disease Reports|June 14, 2023
Progression of Blood-Brain Barrier Leakage in Patients with Alzheimer's Disease as Measured with the Cerebrospinal Fluid/Plasma Albumin Ratio Over TimeChristian Sandøe Musaeus, Helena Sophia Gleerup, Steen Gregers Hasselbalch, et al.
Journal of Alzheimer'S Disease : JAD|April 14, 2020
Cerebrospinal Fluid/Plasma Albumin Ratio as a Biomarker for Blood-Brain Barrier Impairment Across Neurodegenerative DementiasChristian Sandøe Musaeus, Helena Sophia Gleerup, Peter Høgh, et al.
Clinical Biochemistry|December 12, 2022
Cerebrospinal fluid glucose is not altered in patients with dementiaCamilla Steen Jensen, Helena Sophia Gleerup, Christian Sandøe Musaeus, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 14, 2023
Neurofilament light chain levels in serum among a large mixed memory clinic cohort: Confounders and diagnostic usefulnessAnja Hviid Simonsen, Helena Sophia Gleerup, Christian Sandøe Musaeus, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 17, 2025
Plasma biomarkers of amyloid, tau, astrogliosis, and axonal injury in a mixed memory clinic cohortHelena Sophia Gleerup, Anja Hviid Simonsen, Lana Grötschel, et al.
Frontiers in Aging Neuroscience|May 27, 2021
Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic PopulationHelena Sophia Gleerup, Federica Sanna, Peter Høgh, et al.
Pageof 2